

ASX Announcement

27 July 2026

Quarterly Activities Report

For the Quarter Ended 30 June 2026 (Q4 FY26)

Highlights

- **A\$17.5 Million Placement Complete:** Raised A\$17.5 million (before costs) at A\$0.65 per share via placement of shares to sophisticated and institutional investors in order to fund completion of the FDA registrational study for BlinkLab Dx1, European regulatory activities, expansion of the Company's ADHD program, continued platform development, and commercial readiness initiatives.
- **Foundational U.S. Patent Granted:** United States patent granted, covering BlinkLab's core remote neurobehavioural testing technology up until 2041 with exclusivity from Princeton University.
- **South American Research Program:** New collaboration with Ecuador-based ESPOCH for examining autism, sensorimotor function, nutrition, and gut microbiota.
- **Expansion of BlinkLab Platform into Therapy Evaluation:** New partnership and research collaboration with Erasmus University Medical Center, evaluating treatment response to Activated PI3K Delta Syndrome, extending BlinkLab's platform into therapy evaluation and digital endpoints.
- **Continued Global Investor Engagement:** Members of BlinkLab's Board and Management Team presented and attended key opportunities in Australia and the Asia-Pacific region, including the Ignite Investment Summits (Singapore and Hong Kong) and Stocks in the Vines (Australia).
- **Financial Position:** Cash position at 30 June 2026 was ~A\$17.9 million.

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company"), a leading digital healthcare company focused on AI-powered diagnostics, is pleased to provide its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2026 (the "Quarter" or the "Reporting Period").

Commenting on the June Quarter, BlinkLab Co-founder, CEO and Managing Director, Dr Henk-Jan Boele, stated:

"Our pivotal U.S. FDA 510(k) autism program continued to progress according to plan during the quarter and remains our clear priority. We also secured foundational U.S. patent protection for our core technology through to 2041 and strengthened our balance sheet through the A\$17.5 million placement, putting us in a strong position to execute our program. We continue to look forward, with real excitement, to releasing our ADHD study results in the coming days.

What also excites me is seeing our technology being applied to clinical questions beyond paediatric autism and ADHD, from adult autism and lifestyle monitoring to rare genetic disorders, treatment response, nutrition and gut health. These studies help us understand where our platform can provide meaningful information beyond diagnosis and create additional long-term clinical and commercial opportunities."

Overview of Operations

FDA 510(k) Pivotal Study Underway

Paramount to BlinkLab's regulatory progress, the Company continued with the main study phase of its U.S. FDA 510(k) pivotal validation program throughout the June Quarter for the Company's flagship BlinkLab Dx1 technology for autism. With BlinkLab's clinical network of leading autism centres and research institutions across the United States, the Company has continued with recruitment and testing since its first participating child was tested in the previous quarter earlier this year.¹

Expansion to Therapy Evaluation: Collaboration with Erasmus MC

On 19 May 2026, the Company announced its partnership with Erasmus University Medical Center, a leading medical institution in the Netherlands.² The collaboration is centred around the study of treatment-related changes in behavioural and neurodevelopmental function in patients with Activated PI3K Delta Syndrome ("APDS"), which is a rare inborn error of immunity that is increasingly recognised as being associated with neurodevelopmental conditions like autism. The study was designed to monitor behavioural and neurodevelopmental function both before and during treatment with a selective PI3K-delta (PI3Kδ) inhibitor, which is a pathway-targeted therapy for APDS.

Such a study would be strategic for BlinkLab's broader mission, as it moves the Company beyond diagnostics to also incorporate therapy evaluation and digital endpoints for pharmaceutical studies, which is a growing opportunity for a platform technology such as BlinkLab's as more targeted therapies are developed over time. The Company believes its reflex-based and broader sensorimotor neurometric platform can support pharmaceutical companies and academic groups seeking objective, remote and repeatable endpoints for clinical development programs.

Global Footprint Expansion: ESPOCH Research Partnership

On 16 June 2026, the Company announced its new research collaboration with Ecuador-based Escuela Superior Politécnica de Chimborazo (ESPOCH) on a multi-centre study for autism, sensorimotor function, as well as nutrition and gut microbiota.³ The program "Proyecto Wiñay" is to be funded by ESPOCH, while BlinkLab will provide its smartphone-based platform and technical assistance as part of the research collaboration.

The project was announced as a two-year agreement, as part of a broader cooperation framework across five years. The agreement provides that BlinkLab will retain ownership of the technology and data collected throughout the project, generating real-world evidence for further development of the BlinkLab platform, whilst also expanding the Company's global research presence.

Foundational U.S. Patent Granted

On 18 June 2026, the Company announced that it had been granted a U.S. Patent by the USPTO up until 2041 for its technology originally invented by BlinkLab co-founders and Princeton University neuroscientists, Dr Henk-Jan Boele and Professor Samuel S.H. Wang.⁴

¹ ASX Announcement (24 March 2026) – "BlinkLab Commences Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled"

² ASX Announcement (19 May 2026) – "BlinkLab Expands into Therapy Evaluation for Neurodevelopmental Conditions with Erasmus MC"

³ ASX Announcement (16 June 2026) – "BlinkLab Partners with ESPOCH on Large-Scale Multicenter Ecuador Autism and Sensorimotor Study Program"

⁴ ASX Announcement (18 June 2026) – "BlinkLab Granted Foundational U.S. Patent Covering Remote Neurobehavioural Testing Platform"

The patent (U.S. Patent No. 12,653,444 B2), titled “*System and Method for Remote Neurobehavioral Testing*”, grants BlinkLab rights to the technology, covering its systems and methods for remote neurobehavioural assessment using audiovisual stimuli, including conditioned eyeblink responses and prepulse inhibition. BlinkLab holds an exclusive worldwide licence to the technology from Princeton University, and the patent is intended to provide long-term protection within the U.S. healthcare markets, strengthening the Company’s intellectual property portfolio.

European Study Recruitment Complete

On 26 June 2026, the Company provided an update via an announcement on the progress of its European ADHD study in collaboration with Mental Care Group (“MCG”),⁵ which follows its initial pilot study with the leading European mental health care provider, announced in 2024.⁶ The European ADHD study was announced to have completed recruitment and data collection with MCG, testing approximately 375 child participants, and a quality-control review confirmed that the dataset was complete, consistent, and ready for analysis.

Findings from the earlier study with MCG in 2024 formed the basis for expanding this research on ADHD into the present study, which has been designed to evaluate BlinkLab’s objective measures against gold-standard clinical ADHD diagnostic approaches. The study also supports the further development of the BlinkLab Dx2 technology aimed at ADHD, which the placement of shares and capital raised in April of the Quarter will also go toward, with the Company set to launch its U.S. program for ADHD.⁷

Corporate

A\$17.5 million Placement

On 16 April 2026, the Company announced the completion of a successful placement of shares (“Placement”) and capital raising of ~A\$17.5 million (before costs) at A\$0.65 per share, coming from institutional and sophisticated investors. Proceeds from the capital raise were stated to support BlinkLab’s ongoing U.S. FDA 510(k) autism trial, European CE and MDR approvals, working capital, and patent development, as well as towards the launch of the Company’s BlinkLab Dx2 ADHD program.

Ongoing Global Investor Engagement

Throughout the Quarter, BlinkLab continued to engage with investors around Australia and the Asia-Pacific region through a series of opportunities to present and network among institutional investors, industry experts, and other representatives.

On 17 April 2026, the Company announced it had been invited to present at the Ignite Investment Summit events taking place in both Hong Kong (15-16 April) and Singapore (21-22 April), engaging with professional and sophisticated investors from around the Asia-Pacific.⁸

⁵ ASX Announcement (26 June 2026) – “*BlinkLab Provides Update on European ADHD Study*”

⁶ ASX Announcement (30 July 2024) – “*BlinkLab Partners with Mental Care Group in Europe to Improve and Accelerate the Diagnostic Evaluation of ADHD*”

⁷ ASX Announcement (16 April 2026) – “*BlinkLab Secures A\$17.5M to Fund the Launch of Autism Diagnostic Aid and Expand ADHD Program*”

⁸ ASX Announcement (17 April 2026) – “*BlinkLab Invited to Present at Ignite Investment Summits in Hong Kong and Singapore*”

On 14 May 2026, the Company also announced that BlinkLab's Chairman, Mr Brian Leedman, would be presenting at the Stocks in the Vines Investor Access Day in the Yarra Valley, Victoria, in front of private investors, advisory bodies, and Australian family office representatives.⁹

Financial

June Quarter Cash Flows

As at 30 June 2026, BlinkLab reported a cash balance of A\$17.953 million.

For the June Reporting Period, BlinkLab reported net cash used for operating activity of A\$2.612 million, with expenditure for the Quarter primarily used for research and development on the Company's platform and costs associated with support for its ongoing research and clinical study programs (A\$1.811 million). Administration and corporate costs of A\$581k were largely attributable to insurance.

Related Party Payments

In accordance with ASX Listing Rule 4.7C.3 for related party payments, the Quarter included payments of A\$0.215 million comprising Directors fees and superannuation.

Outlook

Moving into the new financial year, BlinkLab is now focused on the completion of its near-term priority milestones, including:

- **European ADHD Study:** Completing the final analysis of the ongoing European ADHD study with Mental Care Group. The reporting of these results is imminent.
- **FDA 510(k) Pivotal Program for Autism:** Continuation of the BlinkLab Dx1 510(k) Pivotal program in the United States, conducted by IQVIA, with patient recruitment expected to be completed by the end of CY2026, as well as progressing regulatory clearance in Europe (CE/MDR).
- **Adult autism diagnostic assessment:** Preparing data for the adult autism diagnostic assessment study with Vrije Universiteit Amsterdam (145 participants, data collection complete), with results expected to be announced in Q4 CY2026.
- **Lifestyle and autism:** Preparing data for the adult autism lifestyle monitoring study combining smartwatch data with BlinkLab neurometrics (552 assessments across 23 participants, data collection complete), with results expected to be announced in Q4 CY2026.
- **Nationwide Moroccan Healthcare System Roll-out:** progressing the nationwide screening program for autism in the Kingdom of Morocco, announced on 23 March 2026, acting as a reference point for scalable use of BlinkLab's platform.¹⁰

This announcement has been authorised for release by the Board of BlinkLab Limited.

⁹ ASX Announcement (14 May 2026) – "BlinkLab to present at Stocks in the Vines Investor Access Day"

¹⁰ ASX Announcement (23 March 2026) – "BlinkLab Selected for Morocco's Nationwide Government-Funded Autism Screening Program"

For further information please contact:

Dr Henk-Jan Boele

Managing Director & CEO

henkjan@blinklab.org

M: +31 (0) 611 132 247

Brian Leedman

Non-Executive Chairman

brian@blinklab.org

M: +61 (0) 412 281 780

About BlinkLab Limited

BlinkLab Limited was founded by neuroscientists at Princeton University and is developing a smartphone-based diagnostic platform for autism. Its most advanced product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence, and machine learning to capture objective, reflex-based measures, supporting earlier and more accurate autism identification. This enables timely intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, and AI, supported by a Scientific Advisory Board of leading experts in autism and brain development.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

BlinkLab Limited

ABN

53 652 901 703

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,811)	(6,146)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(139)	(557)
(d) leased assets	-	-
(e) staff costs	(135)	(304)
(f) administration and corporate costs	(581)	(1,188)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	54	266
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	822
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(2,612)	(7,107)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(3)	(120)
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	(23)	(140)
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(26)	(260)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	17,581	17,791
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	304
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1,245)	(1,252)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Payment of lease liability	(23)	(188)
3.10	Net cash from / (used in) financing activities	16,313	16,655

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,319	8,711
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,612)	(7,107)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(26)	(260)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	16,313	16,655
4.5	Effect of movement in exchange rates on cash held	(41)	(46)
4.6	Cash and cash equivalents at end of period	17,953	17,953

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,883	2,789
5.2	Call deposits	15,070	1,530
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	17,953	4,319

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(215)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities		
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(2,612)
8.2 Cash and cash equivalents at quarter end (item 4.6)	17,953
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	17,953
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	6.87
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2026

Authorised by: The Board of BlinkLab Limited

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.